Lazard Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Lazard Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,160	Closed	-$3K	–	2018
2023 Q4	$3K	Sell	4,160 -193	-4%	-$109	﹤0.01%	2135
2023 Q3	$3K	Buy	4,353 +185	+4%	+$155	﹤0.01%	2187
2023 Q2	$3K	Sell	4,168 -15,130	-78%	-$18K	﹤0.01%	2220
2023 Q1	$20K	Sell	19,298 -79,292	-80%	-$123K	﹤0.01%	2050
2022 Q4	$143K	Buy	+98,590	New	+$160K	﹤0.01%	1381
2018 Q3	–	Sell	-160,892	Closed	-$1.91M	–	1044
2018 Q2	$1.91M	Buy	160,892 +49,210	+44%	+$614K	﹤0.01%	664
2018 Q1	$1.25M	Buy	+111,682	New	+$977K	﹤0.01%	687

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Lazard Asset Management's ADAP Position: Q1 2024 in Review

Lazard Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q1 2024, closing a stake of 4,160 shares — an estimated $3K sold.

Lazard Asset Management first reported a position in ADAP in Q1 2018 and held it in 7 quarters. The position peaked at $1.91M in Q2 2018. 80 funds tracked by Wall St. Rank hold ADAP as of Q1 2024.

Lazard Asset Management reported no remaining Adaptimmune Therapeutics position as of Q1 2024 after selling out during the quarter.
Lazard Asset Management sold 4,160 Adaptimmune Therapeutics shares in Q1 2024, an estimated $3K.
Lazard Asset Management first reported a position in Adaptimmune Therapeutics in Q1 2018 and held it in 7 quarters.
Lazard Asset Management's Adaptimmune Therapeutics position peaked at $1.91M in Q2 2018.
80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2024.

Based on Lazard Asset Management's 13F filing for Q1 2024, filed 14 May 2024.